Redcare Pharmacy Shares Plunge on Disappointing Outlook

Redcare Pharmacy's record revenue fails to offset a €39.4M net loss and a sharply reduced margin target, triggering a 40% stock sell-off as investors focus on profitability.

Investors have delivered a harsh verdict on Redcare Pharmacy's latest financial update. Despite posting record revenue growth, the company's net loss and a significantly lowered profit outlook triggered a massive sell-off. The stock has plummeted approximately 40% since the start of the year, reaching a fresh 52-week low.

Profitability Concerns Overshadow Revenue Gains

The company's 2025 results presented a stark contrast. Revenue surged by 24% to €2.94 billion, primarily driven by the German e-prescription business, where sales nearly doubled with a 98% increase to €503 million. Its customer base also expanded robustly, adding 1.4 million new active users for a total of 13.9 million.

However, this top-line strength failed to translate to the bottom line. Redcare Pharmacy reported a net loss of €39.4 million for the year. While its adjusted EBITDA margin improved from 1.4% to 2.0%, it remains at a level that continues to raise questions about the underlying business model's profitability. A particular weak spot was the higher-margin over-the-counter and beauty segment, which underperformed in the fourth quarter with revenues falling roughly 9% short of analyst forecasts.

Guidance Revision Sparks Investor Flight

The primary catalyst for the steep decline in share price was the company's guidance for 2026. Management now forecasts revenue growth of 13% to 15% and an adjusted EBITDA margin of at least 2.5%. Both projections fell below market expectations. More damaging was the decision to slash the medium-term margin target to just 5%, marking a clear retreat from previously stated, more ambitious goals.

Heavy capital expenditure is further weighing on the financial picture. The leadership team has labeled 2025 and 2026 as peak investment years. In 2025 alone, approximately €119 million was channeled into logistics and automation projects. Investments are not expected to fall below 2% of revenue until after 2026.

The Path Forward: Margins in Focus

A clear pattern has emerged: investors are no longer rewarding revenue growth in isolation. As long as significant capital outlays and intense competitive pressure continue to suppress margins, the stock is likely to remain under pressure. The next key test arrives on May 6, 2026, when Redcare Pharmacy releases its first-quarter results. This report will provide the first concrete indication of whether the company's margin trajectory is aligning with its revised targets.